Loading clinical trials...
Loading clinical trials...
A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers
Conditions
Interventions
Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
Biospecimen Collection
Locations
1
United States
City of Hope Medical Center
Duarte, California, United States
Start Date
June 2, 2022
Primary Completion Date
July 21, 2026
Completion Date
July 21, 2026
Last Updated
September 16, 2025
NCT04657068
NCT07197671
NCT04585750
NCT05831579
NCT04900818
NCT05004116
Lead Sponsor
City of Hope Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions